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Background: Hospital discharge records are an essential source of information when comparing health outcomes
among hospitals; however, they contain limited information on acute clinical conditions. Doubts remain as to
whether the addition of clinical and drug consumption information would improve the prediction of health
outcomes and reduce confounding in inter-hospital comparisons. The objective of the study is to compare the
performance of two multivariate risk adjustment models, with and without clinical data and drug prescription
information, in terms of their capability to a) predict short-term outcome rates and b) compare hospitals’
risk-adjusted outcome rates using two risk-adjustment procedures.
Methods: Observational, retrospective study based on hospital data collected at the regional level.
Two cohorts of patients discharged in 2010 from hospitals located in the Lazio Region, Italy: acute myocardial
infarction (AMI) and hip fracture (HF). Multivariate logistic regression models were implemented to predict 30-day
mortality (AMI) or 48-hour surgery (HF), adjusting for demographic characteristics and comorbidities plus clinical
data and drug prescription information. Risk-adjusted outcome rates were derived at the hospital level.
Results: The addition of clinical data and drug prescription information improved the capability of the models to
predict the study outcomes for the two conditions investigated. The discriminatory power of the AMI model
increases when the clinical data and drug prescription information are included (c-statistic increases from 0.761 to
0.797); for the HF model the increase was more slight (c-statistic increases from 0.555 to 0.574). Some differences
were observed between the hospital-adjusted proportion estimated using the two different models. However,
the estimated hospital outcome rates were weakly affected by the introduction of clinical data and drug
prescription information.
Conclusions: The results show that the available clinical variables and drug prescription information were
important complements to the hospital discharge data for characterising the acute severity of the patients.
However, when these variables were used for adjustment purposes their contribution was negligible. This
conclusion might not apply at other locations, in other time periods and for other health conditions if there is
heterogeneity in the clinical conditions between hospitals.
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Over the last two decades, there has been increasing
interest in the development of performance indicators in
the attempt to promote accountability in health services
[1-3]. These measures may concern different aspects of the
system and reflect different objectives. “Process” measures,
as surrogate outcome indicators, have been used to assess
whether specific care processes recommended in clinical
guidelines are administered, such as intervening within
48 hours of a hip fracture (HF). “Outcome” measures, such
as the 30-day mortality rate after hospital admission for
acute myocardial infarction (AMI), have been used to
evaluate the effectiveness of health care processes.
In this respect, hospital discharge records have been
an essential source of information for comparing health
outcomes among hospitals [4]. They are widely available
and represent a cost-effective source of information for
monitoring health care quality in clinical practice over
large populations and across a wide variety of conditions
and procedures [5,6]. However, the amount of patient-
level information collected in these archives is limited,
generally consisting of age, gender, discharge diagnoses
and main procedures. These data do not allow observers
to characterise the acute clinical severity of the patient,
but only to identify specific diseases as “comorbidities”
(e.g., chronic pre-existing conditions that increase the a
priori risk that the subject will incur adverse short-term
health outcomes) [7,8]. For these reasons, the ability of
administrative data to adjust for the severity of illness
and to provide unbiased estimates of expected mortality
rates at the hospital level has been criticised [9].
On the opposite extreme, clinical or laboratory data
abstracted from medical records, when available, repre-
sent a good alternative because they may better account
for the pre-hospital or pre-operative severity of illness,
they may distinguish comorbidities (conditions already
present at the time of admission or the procedure) from
complications (conditions arising during hospitalisation
or during the procedure) and they do not limit the
number of reported diagnoses, so they avoid differential
reporting of conditions according to the baseline severity
of the patient [10,11]. The main drawbacks of the clin-
ical archives are that their reliability may differ between
hospitals and that it is difficult to obtain a large amount
of clinical data at an affordable cost. Therefore, it is diffi-
cult to implement risk-adjustment methods based on
these data in a systematic way [5,10].
Many authors and physicians advocate integrating both
types of data to take full advantage of their relative
strengths [12]. However, this strategy is often not feasible
in clinical practice because of the difficulty obtaining
timely and complete information on acute clinical severity.
Thus, some investigators [13] have questioned whether it
is possible to identify a limited number of laboratory orclinical data points that would be affordable and easy to
collect from electronic medical archives and could be
used to improve risk adjustment of inpatient mortality
for different clinical conditions or procedures. In other
words, as Johnston and colleagues asked, “Is there a
low-cost way to improve the risk adjustment of adminis-
trative data?” [5].
Following these principles, medical professionals from
different clinical areas and public health authorities began
an audit activity in 2006 in the Lazio Region, Italy, with
the aim of complementing the Hospital Information
System (HIS) with a few selected clinical variables chosen
to better characterise the acute severity of patients admit-
ted for specific conditions. Ultimately, Coronary Artery
Bypass Grafting (CABG), AMI and HF were selected, and
a few clinical or laboratory data points were identified for
each of them. The collection and transmission of this in-
formation became mandatory for all public and private
hospitals in the Lazio region (where Rome is located) in
2008, and the new data became part of the new HIS.
Another information system with strong potential for
comparative effectiveness research is the Regional Drug-
Dispensing Registry (PHARM), which includes individual
records for each drug prescription dispensed in public and
private pharmacies. Some studies have evaluated the use
of pharmacy dispensing data for predicting healthcare util-
isation [14] or to identify patients with chronic conditions
[15] but not specifically to control for confounding.
However, there is extensive scientific literature on the
performance of “a priori” comorbidity scores based on
outpatient pharmacy dispensing data, such as the
Chronic Disease Scores [16-18]. Despite their popular-
ity, these indices have limited utility in controlling for
confounding because, like all summary scores, they as-
sume a fixed relationship between comorbidities and
the outcome, even though this relationship is likely to
differ between populations. In fact, the risk-adjustment
process should involve the construction of empirical ill-
ness severity and comorbidity measures specific to the
study population. From this perspective, the scientific
literature currently has significant gaps in terms of the
evaluation of different types of empirical models for
risk-adjustment procedures.
The integration of diagnosis-based models with
medication-based predictive models is expected to re-
sult in greater predictive power and more exhaustive
control of confounding, by modelling the complex rela-
tionships between diagnosed comorbidities and the
presence of any pharmacological therapy, taking into ac-
count its benefit and harms. Extending these approaches
to different diseases and conditions for developing and
applying risk-adjustment models can provide new evi-
dence to evaluate whether data on hospital performance
are credible or methodologically flawed.
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mortality after AMI admission and surgery within 48 hours
after HF admission, with two objectives: 1) to compare a
risk-adjustment model based on hospital discharge data
only with a model including clinical variables and drug
prescription information and 2) to investigate whether the
two risk-adjustment procedures lead to different conclu-
sions about hospital comparisons.Methods
Data sources
The Lazio Region Hospital Information System (HIS)
collects and manages data on all hospitalisations (regis-
tered in the Hospital Discharge Record, HDR) that have
occurred since 1994 in the Lazio Region, an Italian re-
gion located in central Italy with ∼ 5 700 000 residents
[19]. The HDR contains information on 172 hospitals
(65 public hospital corporations, 95 private hospitals and
12 teaching hospitals) regarding patient characteristics
(gender, place/date of birth, residence, etc.), hospital ad-
mission (date of admission, code of admitting hospital,
admitting ward/specialty division, origin of patient,
etc.), in-hospital transfers (dates and wards/divisions in-
volved), discharge (date, discharging ward, type of dis-
charge, etc.), clinical characteristics of the patient at
discharge (main diagnosis +5 secondary diagnoses), and
procedures performed during the hospital stay (main +5
secondary, with dates).
The New Information System collects data on clinical
variables for all hospitalisations related to AMI and HF
that have occurred in the Lazio Region since 2008. In par-
ticular, for all hospitalisations with a diagnosis code of
AMI (ICD9-CM: 410.xx), the patient’s systolic blood pres-
sure at the time of hospital admission is recorded. For all
hospitalisations with a diagnosis code of HF (ICD9-CM:
820.xx), the pre-operative creatinine level (mg/dl), the
value of the International Normalised Ratio (INR) and the
time of hospital admission are registered. These additional
clinical data were derived from a review process con-
ducted by a panel of relevant clinical experts.
Drug utilisation data were available from the Regional
Drug-Dispensing Registry (PHARM), which comprises in-
dividual records for each medical prescription dispensed
in public and private pharmacies belonging to the regional
health authorities and referring to residents. The registry
is limited to drugs that are reimbursed by the health care
system for outpatients. Drugs are identified by the na-
tional drug register code, which refers to the international
Anatomical Therapeutic Chemical Classification System
(ATC) and allows for the exact quantification of the dis-
pensed drug. Individual patient data and drug-dispensing
dates are reported for every prescription. Drugs dispensed
were linked using the individual identification codes.The study was conducted with the permission of the
Department of Epidemiology of Lazio Regional Health
Service, the regional referral centre for epidemiological re-
search who has full access to anonymized hospitalization




The AMI cohort consists of all patients who were hospi-
talised in the Lazio Region between January 2010 and
November 2010 with a primary diagnosis of AMI (ICD9-
CM= 410.xx) or a secondary diagnosis of AMI and a com-
plication of myocardial infarction as the primary diagnosis
(ICD9-CM diagnosis codes: 423.0, 427.0, 427.1, 427.2,
427.3, 427.4, 427.6, 427.8, 427.9, 429.5, 429.6, 518.4, 780.2,
799.1, 998.2). If the same subject was re-hospitalised for
AMI within 28 days of the first hospital admission, only
the first admission was included, under the assumption
that the following admissions were part of the same AMI
episode. Furthermore, only subjects aged 18–100 years
who resided in the study area were included, and only re-
cords with complete administrative and clinical data were
retained to guarantee complete comparability of the risk-
adjustment models.
For all subjects, information was available on the fol-
lowing parameters: age, gender, systolic blood pressure
and a list of co-morbidities chosen a priori and defined
on the basis of the primary and secondary diagnoses for
all hospital admissions that occurred in the previous
two-year period [20,21]. On the contrary, secondary diag-
noses from the index hospitalisations were considered
only when they did not refer to the diagnoses at discharge
to distinguish between pre-existing conditions and com-
plications that arose after admission. (The complete list of
co-morbidities and details on the ICD9-CM codes are
available on request).
For all patients, information on drug prescriptions was
available from the PHARM registry. We collected informa-
tion on anticoagulants (ATC codes: B01AA and B01AB),
antiplatelet agents (ATC: B01AC), cardiac therapy drugs
(C01), antihypertensive drugs (C02), diuretics (C03), beta-
blocking agents (C07), calcium channel blockers (C08),
ACE inhibitors (C09A and C09B), angiotensin II antago-
nists (C09C and C09D), statins (HMG CoA reductase
inhibitors, C10AA), other lipid-modifying agents (C10
excluding C10AA), and anti-diabetic drugs (A10). Treat-
ment was defined as at least 1 prescription in the 3 months
preceding the AMI admission.
HF cohort
The HF cohort includes all patients hospitalised in the
Lazio Region between January 2010 and November 2010
with a primary or secondary diagnosis of HF (ICD9-CM=
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subjects with HF in the previous two years; 2) subjects
younger than 65 years or older than 100 years; 3) patients
residing outside the Lazio Region; 4) hospitalisations with
a diagnosis of cancer (ICD9-CM: 140–208) on the index
admission or in the previous two years; 5) patients with
multiple trauma (Diagnosis Related Groups - DRG codes:
484–487); 6) hospitalisations in which the patient was
admitted directly to an intensive care unit; and 7) hospita-
lisations in which surgery was not performed and the pa-
tient died within the first 48 hours. Furthermore, only
records with complete administrative and clinical data
were retained to guarantee complete comparability of the
risk-adjustment models.
For all the subjects, information was available on age,
gender, clinical variables, and an extensive list of co-
morbidities [20,22] chosen a priori and defined on the
same basis as reported for AMI cohorts.
For all patients, information on drug use was available
from the PHARM registry. We collected information on
anticoagulants (ATC codes: B01AA, B01AB) and anti-
platelet agents (ATC: B01AC), according to the specific
hypothesis that the presence of these drug treatments
could delay anaesthesia and, consequently, the surgery.
Treatment was defined as at least 1 prescriptions in the
3 months preceding the HF admission.
Study outcomes
We defined two different outcomes:
1. Mortality within 30 days after AMI admission.
Deaths during the study period were identified using
both the HIS (discharge disposition: death) and the
Mortality Information System (MIS).
2. The proportion of interventions performed within
48 hours (0–1 day) of HF admission. The date and
time of hospital arrival corresponded to the date and
time of the index admission.
Statistical analysis
Risk-adjustment models
Multivariate logistic regression models were built for the
study outcomes beginning with the hospital discharge
data only to identify the relevant risk factors among the
variables collected from the HIS. In particular, age and
gender were a priori considered risk factors for all the
study outcomes and were thus included in the risk-
adjustment models regardless of their actual associations
with the outcomes. For the co-morbidities, a bootstrap
stepwise procedure that assigned an importance rank for
the predictors in the logistic regression was imple-
mented to identify the set of conditions that significantly
predicted the risk of the outcome while optimising the
trade-off between the goodness-of-fit of the final modeland parsimony. Using this approach, the logistic regres-
sion with all predictors was run 1000 times on random
samples drawn with replacement from the original data
set. Only the risk factors identified as significant (p ≤ 0.05)
at least 30 times in at least 30% of the procedures were in-
cluded in the predictive model. These steps were used to
define the “hospital discharge data” model.
The “hospital discharge data + clinical variables + drug
prescriptions” model was built in the same way using a
bootstrap stepwise procedure and adding the available
clinical variables and the drug prescription variables to
the set of variables collected from the HIS.
The two risk-adjustment models were compared for each
of the two study outcomes by analysing their discriminatory
power using the “c” statistic, which has been demonstrated
to be equivalent to the area under the receiver-operating
characteristics (ROC) curve [23].
Hospital comparison
To compare outcomes attributed to different hospitals,
we applied the direct standardisation method by creating
a multivariate logistic regression with no intercept and
centred covariates.
This model estimates the log odds of 30-day mortality
and an intervention within 48 hours by hospital. Ad-
justed proportions were obtained for each hospital by
back-transforming parameter estimates using the follow-
ing formula [24]:
Adj proportion ¼ exp estimateð Þ = 1 þ exp estimateð Þð Þ½ k
Where k is a correction coefficient introduced to ac-
count for the non-linear nature of the logistic model.
K is calculated as follows:




Where pj is the adjusted proportion, nj is the group
size, and m is the number of groups.
The adjusted proportions for each hospital were plot-
ted on a funnel plot in which the observed indicator was
plotted against a measure of its precision so that the
control limits form a ‘funnel’ around the target outcomes
(overall 30-day mortality after AMI admission and the
proportion of interventions performed within 48 hours
from HF admission).
A sensitivity analysis using multilevel logistic regres-
sion with a random intercept, for both AMI and HF co-
hort, was performed in order to compare the findings
deriving from the two different approaches.
All statistical analyses were conducted using SAS,
version 9.2 [25].
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Cohort characteristics
The distributions of patient characteristics according to
hospital discharge data, clinical variables and drug pre-
scription data are reported for the two study cohorts in
Table 1.
The AMI cohort consisted of 7613 episodes treated in
62 hospitals: 42 public hospital corporations, 15 private
hospitals and 5 teaching hospitals. There are no substan-
tial differences in patient characteristics between type of
hospitals as shown in (see Additional file 1). A total of
29 (0.38%) records with not complete administrative
and clinical data were excluded. The crude 30-day
mortality rate was 10.8%. The mean age was 70 years,
with a small proportion of women (35%). Among the se-
lected chronic conditions, based on the hospitalisations
in the previous two years, the most frequent conditions
were hypertension (18%), previous myocardial infarction
(15%), diabetes and other forms of ischemic heart dis-
eases (13%). The only clinical variable was the systolic
blood pressure (SBP) collected at the time of hospital
admission, and 10% of the AMI episodes were charac-
terised by SBP values below 100 mmHg. The drug
prescription variables included diuretics (21%), ACE
inhibitors (26%) and angiotensin II antagonists (24%)
prescribed in the three months preceding the hospital
admission.
The HF study population consisted of 6348 hospitali-
sations treated in 83 hospitals: 42 public hospital corpo-
rations, 34 private hospitals and 7 teaching hospitals.
There are no differences in patient characteristics
between type of hospitals as shown in (see Additional
file 2). A total of 10 (0.16%) records with not complete
administrative and clinical data were excluded. The
crude proportion of interventions performed within
48 hours was 19.8%. The characteristics of the HF co-
hort were different from those of the AMI cohort: the
population was older (65–100 years of age) and included
more women (78%). The list of comorbidities was more
extensive: the most frequent were hypertension (14%),
cerebrovascular disease (9%), other forms of ischemic
heart diseases (9%), conduction disorders and arrhyth-
mias (8%) and diabetes (6%). 13% of the patients re-
ported an out-of-range INR value.
Comparison of risk-adjustment models
The risk-adjustment models for AMI and HF are dis-
played in Tables 2 and 3, respectively. Each table re-
ports the variables retained in the final risk-adjustment
models, with the corresponding number of admissions,
crude ORs and adjusted ORs from the “hospital dis-
charge data” model and the “hospital discharge data +
clinical variables + drug prescriptions” model. Finally,
the results from the c-statistics are reported.AMI cohort
Age was a strong predictor of 30-day mortality, with an
adjusted excess risk of dying of 8% for each one-year
increase in age, in both the “hospital discharge data” and
the “hospital discharge data + clinical variables + drug
prescriptions” models. On the contrary, no gender differ-
ences emerged, even after adjusting for age, comorbidities,
clinical variables and drug prescriptions. A long list of
comorbidities were included in the final risk-adjustment
model; other chronic diseases (liver, pancreas, intestine),
heart failure, chronic renal disease, cancer and other forms
of ischemic heart disease had the strongest associations
with mortality. Blood pressure as measured at the time of
hospital admission is strongly associated with 30-day mor-
tality (risk-adjusted OR = 4.60, p-value < 0.001). Interest-
ingly, the OR from the risk-adjusted model is almost
identical to the OR from the crude model, meaning that
the inclusion of past conditions does not alter the predict-
ive power of the SBP. In other words, it seems that this
parameter captures a different dimension of the severity
of the patient’s condition (e.g., acute severity) from that
measured by comorbidities (chronic severity). With regard
to the use of drugs in the 3 months preceding the AMI
admission, the bootstrap stepwise procedure identified
three variables that were significantly associated with the
outcome: the use of diuretics, the use of ACE inhibitors
and the use of angiotensin II antagonists. The effects of
these drugs on 30-day mortality are discordant: while di-
uretics act as a risk factor (adjusted odds ratio: 1.69), ACE
inhibitors and angiotensin II antagonists act as protective
factors (adjusted odds ratios: 0.77 and 0.82, respectively).
As a consequence, the discriminatory power of the
model increases when the clinical data and drug pre-
scription information are included (c-statistic increases
from 0.761 to 0.797).
HF cohort
Age was not associated with the outcome in either the
crude model or the adjusted models; however, gender
differences emerged, even after adjusting for age, comor-
bidities, clinical variables and drug prescriptions. Only
diabetes, obesity and osteoporosis were included in the
final model from the extensive list of conditions defined
a priori. The proportion of patients who received surgery
within the expected 48 hours was half as high for patients
with out-of-range INR compared with patients with in-
range values. With respect to the variables extracted from
the PHARM registry, only the use of antiplatelet agents
was selected in the bootstrap stepwise procedures. Previ-
ous users of platelet aggregation inhibitors were less likely
to receive surgery within 48 hours of hospital admission.
The two risk-adjustment models (“hospital discharge
data” VS “hospital discharge data + clinical variables + drug
prescriptions”) performed equally poorly: the discriminatory
Table 1 Distribution of demographic characteristics, chronic conditions, clinical variables and drug prescriptions
Risk factor AMI HF
(No. 7613) (No. 6348)
No. % No. %
Demographic characteristics
Age (mean, SD) 70.1* 13.5* 83.0* 7.1*
Gender (female) 2690 35.3 4925 77.58
Previous conditions (from HIS)
Cancer 437 5.74
Diabetes 829 10.89 406 6.4
Nutritional deficiencies 18 0.28
Lipid metabolism disorders 344 4.52
Obesity 74 0.97 23 0.36
Blood disorders 338 4.44 322 5.07
Dementia including Alzheimer’s disease 192 3.02
Parkinson’s disease 56 0.88
Hemiplegia and other paralytic syndromes 22 0.35
Rheumatic heart disease 67 0.88 30 0.47
Hypertension 1382 18.15 877 13.82
Previous myocardial infarction 1137 14.93 163 2.57
Other forms of ischemic heart diseases 998 13.11 560 8.82
Acute endocarditis and myocarditis 2 0.03
Cardiomyopathy 95 1.25 50 0.79
Conduction disorders and arrhythmias 592 7.78 479 7.55
Heart failure 554 7.28 356 5.61
Ill-defined descriptions or complications of heart disease 137 1.8 117 1.84
Other heart conditions 103 1.35 82 1.29
Cerebrovascular disease 512 6.73 561 8.84
Vascular disease 304 3.99 154 2.43
Chronic obstructive pulmonary disease (COPD) 423 5.56 366 5.77
Chronic diseases (liver, pancreas, intestine) 85 1.12 71 1.12
Chronic renal disease 419 5.5 232 3.65
Rheumatoid arthritis and other inflammatory polyarthropathies 25 0.39
Osteoporosis and other disorders of bone and cartilage 57 0.9
Previous coronary artery bypass graft 310 4.07
Previous coronary angioplasty 854 11.22
Cerebral revascularisation procedures 42 0.55
Other cardiac operations 47 0.62
Other vascular operations 182 2.39
Clinical data (from the New Information System)
Systolic blood pressure
≤ 100 mmHg 765 10.05
> 100 mmHg 6592 86.59
Missing 256 3.36
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Table 1 Distribution of demographic characteristics, chronic conditions, clinical variables and drug prescriptions
(Continued)
International Normalised Ratio (INR)
0.9-1.2 4,834 76.15




Antiplatelet agents 2447 32.14
Cardiac therapy drugs 1686 22.15
Antihypertensive drugs 359 4.72
Diuretics 1577 20.71
Beta-blocking agents 1554 20.41
Calcium channel blockers 1570 20.62
ACE inhibitors 1977 25.97
Angiotensin II antagonists 1823 23.95
Statins 1885 24.76
Other lipid-modifying agents 557 7.32
Anti-diabetic drugs 1614 21.2
Antiplatelet (3 months) 851 13.41
Anticoagulants (3 months) 238 3.75
*Mean and standard deviation.
aTreatment was defined as at least 1 prescription in the 3 months preceding the AMI/HF admission.
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would have been expected by chance (c = 0.5), with a slight
increase in the c-statistic after the clinical variables and
drug prescriptions were taken into account (c-statistic in-
creased from 0.555 to 0.574).
Hospital comparison
In Figure 1, the hospital-adjusted proportion of 30-day
mortality after AMI admission estimated using the “hos-
pital discharge data” model and the hospital-adjusted pro-
portion estimated using the “hospital discharge data +
clinical variables + drug prescriptions” model are plotted
in a funnel plot.
In Figure 2, the hospital-adjusted proportion of patients
who received an intervention within 48 hours after HF
admission estimated using the “hospital discharge data”
model and the hospital-adjusted proportion estimated
using the “hospital discharge data + clinical variables +
drug prescriptions” model are plotted in a funnel plot.
AMI cohort
The observed mortality rates ranged from 5.4% to 22.2%.
The variability of the adjusted mortality rates from the
two models was different in magnitude, ranging from
6.7% to 22.3% in the “hospital discharge data” model and
from 7.3% to 23.8% in the “hospital discharge data + clin-
ical variables + drug prescriptions” model.Some differences were observed between the hospital-
adjusted proportion estimated using the “hospital dis-
charge data” model and the hospital-adjusted proportion
estimated using the “hospital discharge data + clinical vari-
ables + drug prescriptions” model (Figure 1). However, the
funnel plots clearly reveal that the bulk of hospitals lie
within the 95% limits, and only one hospital lies outside
the 99.8% limits.
HF cohort
The observed proportion of patients who received an
intervention within 48 hours ranged from 2.9% to 63.8%.
The variability of the adjusted proportion from the two
models was different in magnitude, ranging from 2.9%
to 64.4% in the “hospital discharge data” model and
from 3.2% to 65.3% in the “hospital discharge data +
clinical variables + drug prescriptions” model. As ex-
pected in the risk-adjustment models, there was very
close agreement between the observed proportions of
surgery within 48 hours and the expected proportions
derived from the two risk-adjustment models; both
models were not able to characterise the pre-operative
probability of an intervention at the patient level. Thus,
the funnel plots clearly revealed the same pattern when
the hospital-adjusted proportion estimated using the “hos-
pital discharge data” model and the hospital-adjusted pro-
portion estimated using the “hospital discharge data +
Table 2 Predictive models for 30-day mortality after AMI admission (No. 7613)
Risk factor n (admissions) Crude OR Hospital discharge
data
Hospital discharge data + clinical
variables + drug prescriptions
Adjusted OR P Adjusted OR P
Age - 1.08 1.08 0.000 1.08 0.000
Gender (females vs males) 2690 1.66 0.97 0.738 0.96 0.589
Cancer 437 1.87 1.44 0.008 1.42 0.013
Diabetes 829 1.54 1.34 0.013
Disorders of lipid metabolism 344 0.42 0.42 0.001 0.46 0.004
Blood disorders (index admission) 393 1.39 0.69 0.027
Blood disorders 338 2.34 1.28 0.127
Previous AMI 1137 0.85 0.76 0.033 0.71 0.010
Heart failure 554 2.55 1.66 0.000 1.51 0.003
Other forms of ischemic heart disease (index admission) 175 0.88 0.48 0.009 0.47 0.008
Other forms of ischemic heart disease 103 1.41 1.33 0.384 1.26 0.478
Chronic renal disease 419 2.68 1.65 0.000 1.48 0.007
Other chronic disease (liver, pancreas, intestine) 85 2.08 1.92 0.035
Previous CABG 310 0.50 0.50 0.007 0.52 0.012
Previous PCI 854 0.47 0.61 0.004 0.62 0.006
Blood pressure > 100 6592 1.00 1.00 -
Blood pressure < =100 765 4.07 4.60 0.000
Blood pressure missing 256 1.27 1.33 0.195
Diuretics (3 months) 1577 2.54 1.69 0.000
ACE inhibitors (3 months) 1977 1.12 0.77 0.005
Angiotensin II antagonists (3 months) 1823 1.01 0.82 0.039
Area under ROC curve 0.761 0.797
Table 3 Predictive models for surgery performed within 48 hours of HF admission (No. 6348)
Risk factor n (admissions) Crude OR Hospital discharge data Hospital discharge data + clinical
variables + drug prescriptions
Adjusted OR P Adjusted OR P
Age - 1.00 1.00 0.420 1.00 0.456
Gender (females vs males) 4925 1.42 1.40 0.000 1.37 0.000
Diabetes 406 0.66 0.72 0.036 0.68 0.011
Obesity (index admission) 41 2.36 2.21 0.016 2.33 0.011
Obesity 23 1.13 1.22 0.705 1.04 0.935
Hypertension 877 0.76 0.80 0.028
Osteoporosis 57 2.05 2.13 0.008 1.97 0.017
INR 0.9-1.2 4834 1.00 -
INR out of range 855 0.57 0.56 0.000
INR missing 659 0.83 0.78 0.023
Antiplatelet (3 months) 851 0.78 0.79 0.020
Area under ROC curve 0.555 0.574
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Figure 1 Adjusted 30-day mortality after AMI admission, by hospital (No. 7613).
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(Figure 2).
With regard to the sensitivity analysis, multilevel and
fixed-effects models lead to similar results: both random
and fixed effects analyses showed that adding clinical
variables to the adjusting models did not modify the
hospital ranking.
Discussion
The present study was designed to quantify the additional
contribution of clinical variables and drug prescription in-
formation in predicting short-term outcome rates and
profiling hospitals compared to the use of hospital dis-
charge data alone. We found that the risk adjustment
improved considerably for the AMI cohort after the three
sources of data were integrated, whereas the two risk-
adjustment models performed equally poorly for the HF
cohort. However, hospital profiling was not affected by theuse of clinical variables and drug prescriptions for the HF
cohort, whereas for the AMI cohort, some differences in
hospital profiles were observed even if the “low perform-
ing” and the “best performing” institutions were the same
regardless of the risk adjustment model applied.
The optimal approach to producing hospital outcome
reports relies on collecting valid information to provide
an accurate risk adjustment. This approach requires
medical chart abstraction, which is expensive and there-
fore has not been widely implemented by public reporting
agencies. Using administrative data for public outcomes
reporting offers several advantages, including minimal
data collection costs and the ability to produce reports for
a large number of procedures and conditions [26]. How-
ever, these data do not capture important clinical informa-
tion about the acute severity of the patient and do not
distinguish between the conditions that were present at
admission and the complications that occurred during
Figure 2 Adjusted proportion of interventions performed within 48 hours of HF admission, by hospital (No. 6348).
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http://www.biomedcentral.com/1472-6963/14/495hospitalisation [7,27,28]. Many authors have advocated for
identifying a limited number of affordable and easily ac-
cessible laboratory or clinical data points from electronic
medical archives that would improve risk-adjustment
models of inpatient mortality for different clinical con-
ditions or procedures [12]. On this basis, in the present
study, we used clinical information from the upgraded
version of the HDR, including a few selected clinical
variables chosen to better characterise the acute sever-
ity of patients admitted for AMI and HF. The Lazio
HIS information is widely available and high in quality,
and it represents a highly cost-effective solution for
monitoring health care quality in clinical practice over
large populations and across a wide variety of condi-
tions and procedures.
The conditions to integrate from the discharge abstracts
and the clinical variables to add were derived from an ex-
tensive audit activity that was conducted beginning in2006 in the Lazio Region, Italy by medical professionals
from different clinical areas and public health authorities.
They opted for AMI and HF, conditions that pose signifi-
cant public health problems, and identified a few clinical
parameters (blood pressure and INR) that could be de-
tected at affordable costs and are considered valid and re-
liable markers of acute severity.
The present study has some important strengths. It is
the first study conducted in Italy with the specified aim
of comparing the performance of risk-adjustment models
with and without clinical variables and drugs prescription
information in the context of hospital profiling and com-
parative outcomes research in general. The high number
of patients investigated, the accuracy in the selection of
the cohorts and the study outcomes, the consolidated stat-
istical strategy, and the replication of similar findings for
different clinical conditions are important elements of in-
ternal and external validity.
Colais et al. BMC Health Services Research 2014, 14:495 Page 11 of 12
http://www.biomedcentral.com/1472-6963/14/495A limitation of this study is the generalizability of our
results due to selection of only hospitalizations from
Lazio region, however the large number of residents and
hospitals in this region minimize the variability of case-
mix between the admission in Lazio hospitals and in
other Italian hospitals. Other limitations should also be
acknowledged, especially the marked variability in the
coding accuracy of current health care information sys-
tems. This issue is critical for ensuring accurate risk ad-
justment and thus reliable comparative quality ratings
[29]. However, data derived from health information sys-
tems are currently utilised to compare inpatient care
outcomes in Italy [30,31] and have proved to be an ac-
curate source for healthcare research and a reliable data
source for adjusting for risk factors [8,32].
Moreover, as in the case of HF, risk-adjustment models
may not be able to predict the study outcome (surgical
treatment), even when they include valid clinical infor-
mation on the severity of disease and drug prescriptions.
This result simply means that the determinants of the
outcome should be sought among the characteristics of
the hospital and health care, which is the eventual pur-
pose of hospital comparisons.
More generally, in outcome comparisons between hos-
pitals, where each hospital represents a level of exposure,
potential clinical confounders cannot produce important
changes in the adjusted measures of association if these
factors are not heterogeneously distributed between hos-
pitals, even when they are strongly associated with the
outcome under study.Conclusions
In conclusion, the present study represents the first
effort in Italy to compare the performance of risk-
adjustment procedures incorporating clinical variables
and drug prescriptions in predicting short-term out-
comes and in profiling hospitals on the basis of the pre-
dicted outcomes. We found that the available clinical
variables and drug prescription information were im-
portant complements to the hospital discharge data for
characterising the acute severity of the patients for one
of the two conditions we analysed. However, when the
output of the predictive models was used to compare
the hospitals on the basis of their risk-adjusted out-
comes, the contribution of the clinical variables and
drug prescriptions was always negligible. We hope that
this approach will be replicated in other studies, for
other clinical conditions, and for different clinical pa-
rameters and alternative analytical procedures to better
interpret the present results and to better understand
the trade-off between the costs and the advantages of
including relevant clinical variables in systematic health
information systems.Data used for the study
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